Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-Liang Ho

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Cancers|January 26, 2019
Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection-A Double Blind, Multi-Center, Randomized Phase IV StudyCheng-Hsu Wang, Cheng-Yao Lin, Jen-Shi Chen, et al.
Cell Death Discovery|March 12, 2019
Fucosyltransferase 1 and 2 play pivotal roles in breast cancer cellsTai-Yu Lai, I-Ju Chen, Ruey-Jen Lin, et al.
Oncogene|September 30, 2018
CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemiaYun-Jung Chiang, Wei-Ting Liao, Kun-Chin Ho, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|July 26, 2014
Distinct MR Imaging Features of Triple-Negative Breast Cancer with Brain MetastasisRen-Hua Yeh, Jyh-Cherng Yu, Chi-Hong Chu, et al.
Plos One|March 9, 2016
The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional AnalysisYi-Ying Wu, Tzu-Chuan Huang, Tsung-Neng Tsai, et al.
Hematological Oncology|June 20, 2017
Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myelomaShang-Yi Huang, Cheng-Shyong Chang, Ta-Chih Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 24, 2014
Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinomaKai-Hsiung Ko, Hsian-He Hsu, Tsai-Wang Huang, et al.
JCO Oncology Practice|December 9, 2025
Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety OutcomesRen-Hua Ye, Hong-Jie Jhou, Hsin-Yu Chen, et al.
JCO Oncology Practice|May 6, 2026
Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung CancerPo-Huang Chen, Hong-Jie Jhou, Wei-Cheng Chang, et al.
Frontiers in Cell and Developmental Biology|August 22, 2022
Large-scale transcriptomic analysis of coding and non-coding pathological biomarkers, associated with the tumor immune microenvironment of thyroid cancer and potential target therapy explorationMing-Lang Shih, Bashir Lawal, Sheng-Yao Cheng, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Cancers|January 26, 2019
Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection-A Double Blind, Multi-Center, Randomized Phase IV StudyCheng-Hsu Wang, Cheng-Yao Lin, Jen-Shi Chen, et al.
Cell Death Discovery|March 12, 2019
Fucosyltransferase 1 and 2 play pivotal roles in breast cancer cellsTai-Yu Lai, I-Ju Chen, Ruey-Jen Lin, et al.
Oncogene|September 30, 2018
CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemiaYun-Jung Chiang, Wei-Ting Liao, Kun-Chin Ho, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|July 26, 2014
Distinct MR Imaging Features of Triple-Negative Breast Cancer with Brain MetastasisRen-Hua Yeh, Jyh-Cherng Yu, Chi-Hong Chu, et al.
Plos One|March 9, 2016
The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional AnalysisYi-Ying Wu, Tzu-Chuan Huang, Tsung-Neng Tsai, et al.
Hematological Oncology|June 20, 2017
Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myelomaShang-Yi Huang, Cheng-Shyong Chang, Ta-Chih Liu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 24, 2014
Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinomaKai-Hsiung Ko, Hsian-He Hsu, Tsai-Wang Huang, et al.
JCO Oncology Practice|December 9, 2025
Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety OutcomesRen-Hua Ye, Hong-Jie Jhou, Hsin-Yu Chen, et al.
JCO Oncology Practice|May 6, 2026
Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung CancerPo-Huang Chen, Hong-Jie Jhou, Wei-Cheng Chang, et al.
Frontiers in Cell and Developmental Biology|August 22, 2022
Large-scale transcriptomic analysis of coding and non-coding pathological biomarkers, associated with the tumor immune microenvironment of thyroid cancer and potential target therapy explorationMing-Lang Shih, Bashir Lawal, Sheng-Yao Cheng, et al.
Pageof 16